- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Science
- Onco-Metabolism Platform
- Therapeutic Areas
- Publications
- Programs
- Pipeline
- Glutaminase Inhibitor Telaglenastat
- Arginase Inhibitor INCB001158
- Arginase Inhibitor
CB-280 - CD73 Inhibitor
CB-708 - Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Media & Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
Science
Publications and Presentations
Check out our publications and poster presentations.
July 2016
CB-1158 Inhibits the Immuno-oncology Target Arginase and Causes an Immune Mediated Anti-Tumor ResponseCharles River Symposium-Immunotherapy
June 2016
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, alone and in combination with everolimus in patients with renal cell cancer Phase 1 study of CB-839, a small molecule inhibitor of glutaminase in combination with paclitaxel in patients with triple negative breast cancerAmerican Society of Clinical Oncology – June 2016
April 2016
Immuno-Oncology Agent CB-1158 is a Potent and Selective Arginase Inhibitor and Causes an Immune-Mediated Anti-Tumor ResponseAmerican Association of Cancer Research – April 2016
April 2016
Glutaminase Inhibition With CB-839 Enhances Anti-Tumor Activity of PD-1 and PD-L1 Antibodies by Overcoming a Metabolic Checkpoint Blocking T Cell ActivationAmerican Association of Cancer Research – April 2016
March 2016
Arginase Inhibitor CB-1158 is a Novel Immuno-Oncology Agent that Targets Tumor-Infiltrating Suppressive Myeloid CellsKeystone Symposia on Cancer Immunotherapy
Our Pipeline
We are focused on solid tumors for
which new treatments are urgently needed.